Drugs / Glecaprevir/pibrentasvir
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03855917 | Feb 2020 → Feb 2026 | hepatitis C virus infection | Kirby Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glecaprevir/pibrentasvir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03855917 ↗ |
| Action | Inhibit | “an NS3/4a protease inhibitor and NS5A inhibitor” NCT03855917 ↗ |